🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 19/09/2000 | 80,00 | 83,38 | 79,75 | 82,88 | +3,84% | 4,53% | 629.700 |
| 18/09/2000 | 79,88 | 82,50 | 77,63 | 79,81 | -0,70% | 6,10% | 1.288.900 |
| 15/09/2000 | 78,72 | 80,50 | 77,25 | 80,38 | +4,55% | 4,13% | 1.197.900 |
| 14/09/2000 | 77,31 | 78,25 | 75,88 | 76,88 | +1,49% | 3,07% | 2.854.200 |
| 13/09/2000 | 76,38 | 76,56 | 73,50 | 75,75 | -2,73% | 4,01% | 3.575.500 |
| 12/09/2000 | 77,75 | 78,50 | 75,50 | 77,88 | +5,08% | 3,86% | 2.181.600 |
| 11/09/2000 | 83,25 | 83,44 | 73,50 | 74,11 | -14,01% | 11,94% | 1.022.200 |
| 08/09/2000 | 87,13 | 89,00 | 83,25 | 86,19 | +0,51% | 6,60% | 1.253.900 |
| 07/09/2000 | 79,75 | 86,13 | 79,63 | 85,75 | +8,54% | 8,15% | 512.000 |
| 06/09/2000 | 82,00 | 82,00 | 76,00 | 79,00 | -3,51% | 7,32% | 1.390.800 |
| 05/09/2000 | 88,88 | 88,94 | 80,50 | 81,88 | -4,80% | 9,49% | 765.200 |
| 01/09/2000 | 89,00 | 89,00 | 83,13 | 86,00 | +1,18% | 6,60% | 918.700 |
| 31/08/2000 | 84,75 | 86,38 | 81,52 | 85,00 | +6,92% | 5,73% | 1.050.200 |
| 30/08/2000 | 75,88 | 80,31 | 75,50 | 79,50 | +4,26% | 6,34% | 468.100 |
| 29/08/2000 | 76,38 | 80,75 | 75,00 | 76,25 | -0,97% | 7,53% | 717.200 |
| 28/08/2000 | 80,38 | 80,50 | 75,13 | 77,00 | -3,22% | 6,69% | 1.279.300 |
| 25/08/2000 | 77,94 | 84,44 | 77,00 | 79,56 | +1,52% | 9,54% | 1.020.100 |
| 24/08/2000 | 71,63 | 78,56 | 70,00 | 78,38 | +8,06% | 11,95% | 2.092.200 |
| 23/08/2000 | 68,88 | 75,13 | 68,00 | 72,53 | +3,71% | 10,34% | 2.400.000 |
| 22/08/2000 | 67,97 | 70,06 | 66,50 | 69,94 | +3,42% | 5,24% | 1.465.000 |
| 21/08/2000 | 71,25 | 71,75 | 65,56 | 67,63 | -5,54% | 8,68% | 1.274.600 |
| 18/08/2000 | 69,00 | 73,56 | 68,50 | 71,59 | +3,76% | 7,34% | 1.579.600 |
| 17/08/2000 | 64,38 | 69,88 | 64,00 | 69,00 | +7,18% | 9,13% | 1.632.000 |
| 16/08/2000 | 61,66 | 65,13 | 61,53 | 64,38 | +3,73% | 5,83% | 1.514.000 |
| 15/08/2000 | 61,89 | 62,25 | 59,75 | 62,06 | +0,40% | 4,04% | 607.200 |
| 14/08/2000 | 61,13 | 62,50 | 60,38 | 61,81 | +1,33% | 3,48% | 935.200 |
| 11/08/2000 | 56,53 | 62,50 | 56,53 | 61,00 | +7,02% | 10,56% | 1.054.200 |
| 10/08/2000 | 61,00 | 61,95 | 55,13 | 57,00 | -7,88% | 11,19% | 812.600 |
| 09/08/2000 | 60,25 | 62,94 | 59,75 | 61,88 | +3,34% | 5,29% | 913.400 |
| 08/08/2000 | 59,91 | 61,50 | 58,69 | 59,88 | -0,78% | 4,69% | 752.600 |